Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-78934804 versus guselkumab in moderately to severely active Crohn's disease
NL-OMON61430Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of guselkumab + golimumab and guselkumab in Crohn's disease (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Clinical remission at Week 48 and Endoscopic remission at Week 48. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
guselkumab + golimumabguselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON61430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61430.